Severe Combined Immunodeficiency (SCID)

← Back to Index (🦠 Infectious Diseases)

Definition And Pathogenesis

Severe combined immunodeficiency (SCID) represents the most severe form of primary immune deficiency.
It is a true pediatric immunologic emergency.
The disorder is caused by diverse pathogenic gene variants.
These variants lead to the profound absence of T-cell and B-cell function.
The fundamental defect disrupts lymphoid cell development in both the thymus and peripheral tissues.
Affected infants present with very small thymuses.
The thymus contains no thymocytes.
The thymus lacks corticomedullary distinction.
It is completely devoid of Hassall's corpuscles.
The thymic epithelium itself appears histologically normal.
Peripheral lymphoid structures are also severely affected.
The follicular and paracortical areas of the spleen are depleted of lymphocytes.
Lymph nodes, tonsils, adenoids, and Peyer patches are absent or extremely underdeveloped.
Without definitive immunologic reconstitution, death usually occurs during the first year of life.
The disease is almost invariably fatal before 2 years of age without proper treatment.

Genetic Classification And Phenotypes

SCID exhibits significant genetic heterogeneity.
The disorders are primarily categorized based on the presence or absence of specific lymphocyte populations.
These populations include T cells, B cells, and Natural Killer (NK) cells.
The four most common types of SCID are the X-linked form, autosomal recessive RAG1 and RAG2 deficiencies, and adenosine deaminase (ADA) deficiency.

T- B+ Severe Combined Immunodeficiency

This category is characterized by absent T cells but normal or elevated numbers of B cells.

Disease Subtype	Inheritance	Pathogenesis	Additional Clinical Features
X-linked SCID	X-linked	Pathogenic variants in the IL2RG gene encoding the common gamma chain (CD132). This disrupts signaling for IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 receptors.	Represents the most common form of SCID. Patients lack both T and NK cells (T- B+ NK-).
JAK3 Deficiency	Autosomal recessive	Defective Janus kinase 3 (JAK3) disrupts signaling downstream of the common gamma chain.	Results in an identical lymphocyte phenotype to X-linked SCID (T- B+ NK-) but affects both males and females.
IL-7R-alpha Deficiency	Autosomal recessive	Abnormal interleukin-7 receptor signaling impairs T-cell development.	Presents with a T- B+ NK+ phenotype. The thymus is absent.
CD45 Deficiency	Autosomal recessive	Defective CD45 function.	Presents with a T- B+ NK+ phenotype.
CD3 Deficiencies	Autosomal recessive	Variants in CD3-delta, CD3-epsilon, or CD3-zeta chains cause an arrest of thymocyte differentiation at the CD4- CD8- stage,.	Thymus size may remain anatomically normal.
Coronin-1A Deficiency	Autosomal recessive	Abnormal T-cell egress from thymus and lymph nodes.	Normal thymus size. Associated with attention deficit disorder.

T- B- Severe Combined Immunodeficiency

This category is characterized by the profound absence of both mature T cells and B cells.

Disease Subtype	Inheritance	Pathogenesis	Additional Clinical Features
ADA Deficiency	Autosomal recessive	Adenosine deaminase (ADA) deficiency causes an accumulation of toxic purine nucleosides.	Associated with neurologic, hepatic, and renal abnormalities. Patients also develop pulmonary alveolar proteinosis and chondroosseous dysplasia.
RAG1 and RAG2 Deficiencies	Autosomal recessive	Defective V(D)J recombination impairs the generation of T and B cell receptors.	Presents with a T- B- NK+ phenotype.
Reticular Dysgenesis	Autosomal recessive	Pathogenic variants in the adenylate kinase 2 (AK2) gene impair mitochondrial energy metabolism and leukocyte differentiation.	Characterized by profound SCID accompanied by severe neutropenia and sensorineural deafness.
Artemis Deficiency	Autosomal recessive	Defective V(D)J recombination caused by DCLERE1C variants.	Patients demonstrate marked radiation sensitivity.
DNA Ligase IV Deficiency	Autosomal recessive	Defective nonhomologous end joining and V(D)J recombination.	Associated with marked radiation sensitivity, microcephaly, growth delay, and bone marrow abnormalities.
Cernunnos-XLF Deficiency	Autosomal recessive	Defective V(D)J recombination.	Features include radiation sensitivity, microcephaly, growth delay, and birdlike facies.

Clinical Manifestations

Infectious Manifestations

Infants typically present with severe infections during early infancy if not detected by newborn screening.
Common initial presentations include chronic diarrhea, recurrent pneumonia, persistent otitis media, sepsis, and severe cutaneous infections.
Patients demonstrate an extreme susceptibility to opportunistic pathogens.
Severe oral thrush from Candida albicans is a classic hallmark.
Pulmonary infections are frequently caused by Pneumocystis jiroveci (PJP).
Common respiratory viruses cause severe, life-threatening illness.
These viral agents include parainfluenza 3 virus, adenovirus, respiratory syncytial virus (RSV), cytomegalovirus (CMV), and Epstein-Barr virus (EBV).
Administration of live-attenuated vaccines results in life-threatening, disseminated vaccine-strain infections.
Disseminated bacille Calmette-Guérin (BCG) infection is a frequent presenting feature in regions where the vaccine is administered at birth.
Other contraindicated live vaccines include oral polio virus, rotavirus, measles-mumps-rubella-varicella (MMRV), and yellow fever vaccines.

Non-Infectious And Syndromic Features

Infants with SCID completely lack the cellular immunity required to reject foreign tissues.
Transplacental passage of maternal T lymphocytes during pregnancy can cause severe maternal engraftment graft-versus-host disease (GVHD),.
Maternal engraftment GVHD manifests with a generalized rash, hepatosplenomegaly, intractable diarrhea, and the uncontrolled expansion of allogeneic cells.
Omenn syndrome is a specific variant caused by hypomorphic pathogenic variants in SCID-associated genes.
These hypomorphic variants allow the generation of a few oligoclonal T cells.
These autologous cells expand in an unregulated manner and attack host tissues.
Omenn syndrome clinically mimics GVHD.
It presents with severe generalized erythroderma, scaly desquamating skin, alopecia, massive lymphadenopathy, hepatosplenomegaly, and intractable diarrhea.
Laboratory features of Omenn syndrome uniquely include striking eosinophilia and massively elevated serum IgE levels.
Unirradiated blood transfusions can introduce viable donor T-lymphocytes into the infant.
This iatrogenic exposure uniformly causes fatal transfusion-associated GVHD.
Symptoms of transfusion-associated GVHD include fever, maculopapular rash, Coombs-positive hemolytic anemia, thrombocytopenia, and protein-losing enteropathy.

Diagnostic Evaluation

Newborn Screening

Newborn screening has dramatically improved survival rates by allowing early diagnosis and treatment prior to the onset of systemic infections.
The screening assay utilizes a quantitative polymerase chain reaction (PCR) to measure T-cell receptor excision circles (TRECs) from dried blood spots.
TRECs are episomal DNA byproducts formed during the V(D)J rearrangement of T-cell receptor genes.
TRECs do not replicate during cell division.
They serve as a highly accurate biomarker for enumerating recent thymic emigrants.
A low or absent TREC count identifies infants with severe T-cell lymphopenia and mandates immediate immunologic evaluation.
Kappa excision circles (KRECs) are generated during B-cell development.
Assaying KRECs simultaneously with TRECs allows for the identification of broader SCID phenotypes and congenital agammaglobulinemia.

Laboratory Investigations

A complete blood count typically reveals persistent and profound lymphopenia.
However, a normal absolute lymphocyte count does not reliably rule out SCID.
A falsely normal count can occur due to the uncontrolled proliferation of maternal T cells, autologous B cells, or NK cells.
Flow cytometry is mandatory to precisely quantitate lymphocyte subsets, including T cells, B cells, and NK cells.
Flow cytometric analysis of CD45 isoforms differentiates naive T cells (CD45RA) from memory T cells (CD45RO).
A predominance of memory T cells strongly suggests maternal engraftment or Omenn syndrome.
Identification of a limited T-cell receptor repertoire is also helpful in the diagnosis of Omenn syndrome.
Functional T-cell evaluation is conducted through lymphocyte proliferation assays.
A proliferative response to the mitogen phytohemagglutinin (PHA) of less than 10% of a normal control confirms severe combined immunodeficiency.
Fluorescence in situ hybridization (FISH) targeting the X and Y chromosomes can be utilized in male infants to confirm the presence of engrafted maternal (XX) T cells.
Definitive diagnosis requires targeted gene sequencing using a primary immunodeficiency gene panel to identify the specific pathogenic variant.
Genetic diagnosis is critical for guiding conditioning regimens and evaluating gene therapy options.
Early identification of specific pathogenic variants associated with increased radiation sensitivity helps avoid or reduce dosages of conditioning agents.

Management And Treatment

Supportive Care And Infection Mitigation

SCID constitutes a medical emergency requiring immediate strict isolation to limit exposure to infectious agents.
The number of people in contact with the infant must be strictly limited.
Breastfeeding should be withheld until the CMV and EBV statuses of both the mother and the infant are definitively established.
Infection can be transmitted via breast milk.
Immunoglobulin replacement therapy is warranted immediately at diagnosis.
Maternally derived IgG rapidly wanes after birth, necessitating ongoing immunoglobulin therapy to prevent bacterial illnesses.
Antimicrobial prophylaxis must be initiated promptly at 4 to 6 weeks of age.
Prophylaxis regimens must cover Pneumocystis jiroveci alongside specific viral and fungal pathogens.
Administration of palivizumab is recommended during respiratory syncytial virus (RSV) season for children under 2 years of age to prevent severe lower respiratory tract disease.
Administration of any live-attenuated viral or bacterial vaccines is strictly contraindicated,.
To prevent fatal transfusion-associated GVHD, all administered blood products must be exclusively irradiated or frozen.

Definitive Curative Therapies

Allogeneic hematopoietic stem cell transplantation (HSCT) remains the most important and effective therapy for SCID.
Survival rates approach 95% when HSCT is performed optimally within the first 100 days of life.
Outcomes are highly favorable if performed prior to the onset of systemic opportunistic infections.
Transplantation utilizing an HLA-identical sibling donor is preferred and offers the highest probability of survival,.
Infants with SCID who lack residual NK cell activity or maternal T-cell engraftment can sometimes receive HSCT without any preceding myeloablative conditioning regimen.
In these unconditioned cases, the donor lymphoid cells are usually the only elements that engraft.
Gene therapy utilizing ex vivo gene transfer to autologous hematopoietic stem cells has demonstrated significant success for X-linked SCID and ADA-SCID.
Modern clinical trials utilize lentiviral vectors.
The transition to lentiviral vectors has successfully minimized the risk of insertional mutagenesis and secondary leukoproliferative complications associated with earlier retroviral therapies.
For patients with ADA-SCID, regular intramuscular injections of polyethylene glycol-modified adenosine deaminase (PEG-ADA) can be utilized.
Enzyme replacement therapy provides some immune restoration, although it is not as robust or effective as HSCT or gene therapy.